Pfizer Inc. believes new partner Nodality Inc.'s Single Cell Network Profiling technology will provide early insight into a compound's clinical profile, which could help reduce attrition rates, accelerate development and improve patient selection.

The SCNP technology allows functional analysis of a candidate compound's effect on an intracellular network of targets in a single screen.